國家衛生研究院 NHRI:Item 3990099045/15386
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856875      Online Users : 949
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15386


    Title: TASL-TSOC Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases
    Authors: Cheng, PN;Chen, WJ;Hou, CJ;Lin, CL;Chang, ML;Wang, CC;Chang, WT;Wang, CY;Lin, CY;Hung, CL;Peng, CY;Yu, ML;Chao, TH;Huang, JF;Huang, YH;Chen, CY;Chiang, CE;Lin, HC;Li, YH;Lin, TH;Kao, CH;Wang, TD;Liu, PY;Wu, YW;Liu, CJ
    Contributors: Institute of Cellular and Systems Medicine
    Abstract: Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasingly important and common liver disease worldwide. The diagnosis of MAFLD is based on the presence of steatosis on image/histology/serum markers accompanied with presence of at least one of the three metabolic features that include overweight/obesity, type II diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a contributing or related factor of cardiovascular diseases (CVD) which lead to the major etiology of morbidity and mortality in patients with MAFLD. Hence, understanding the association of MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and current status of management of MAFLD are urgently needed for both hepatologist and cardiologist. The purpose of this Taiwan position statement is to review literature and provide suggestions that cover from epidemiology, etiology, risk factors, risk stratification, non-pharmacological intervention, and potential drug treatment of MAFLD, especially focusing on association with CVD.
    Date: 2024-01
    Relation: Clinical and Molecular Hepatology. 2024 Jan;30(1):16-36.
    Link to: http://dx.doi.org/10.3350/cmh.2023.0315
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2287-2728&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001186681200009
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85181726040
    Appears in Collections:[Chao-Yung Wang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB37793641.pdf1511KbAdobe PDF106View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback